Skip to main content
Fig. 5 | Journal of Experimental & Clinical Cancer Research

Fig. 5

From: Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models

Fig. 5

3D185 strongly inhibited FGFR-driven tumor growth in vivo. A-F, Antitumor efficacy of 3D185 in NCI-H1581 (a-c) and SNU16 (d-f) xenografts. Tumor growth inhibition after treatment with 3D185 is shown. The RTVs are presented as the mean ± SEM (a, d). Tumor weights (g) (b, e) and images of isolated subcutaneous xenograft tumors (c, f) are shown on the day after mice completed the 3D185 treatment course. *p < 0.05; **p < 0.01; ***p < 0.001, as determined by one-way ANOVA with Tukey’s multiple-comparison test. g 3D185 inhibited FGFR signaling in vivo. The intensity of phosphorylated protein band was quantified and normalized with the corresponding internal control protein band (right panel). Mice bearing NCI-H1581 subcutaneous tumor xenografts received a single oral dose of 3D185. Tumors were harvested at 6 h after treatment, and intratumoral p-ERK levels were tested by immunoblotting. h-i IHC evaluation of Ki67 (h) and CD31 (i) expression was performed in NCI-H1581 and SNU16 xenograft models after the final dose of 3D185 (scale bars, 100 μm)

Back to article page